P-178 Rego-Nivo II-III: Proof-of-concept phase II trial for the treatment of HCC refractory to chemotherapy after the 2nd line

Abstract

Atezolumab and bevacizumab combination is the worldwide gold standard in first-line systemic treatment of advanced or metastatic HCC. In contrast, immunotherapy alone did not show a significal benefit in terms of overall survival in the second line. No clinical trial has assessed combined treatment so far beyond the second line. The aim of this proof-of-concept study was to evaluate the benefit of a combination of regorafenib plus nivolumab in a series of patients with advanced HCC with progression after 2 or more lines of oral chemotherapy and who did not have access to atezolumab and bevacizumab.